SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J Bae, R Prabhala, A Voskertchian, A Brown, C Maguire, P Richardson, G Dranoff, K C Anderson, N C Munshi, A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients, Leukemia, 2014,

    CrossRef

  2. 2
    Saad Zafar Usmani, How long can we let the myeloma smolder?, Expert Review of Hematology, 2014, 7, 1, 17

    CrossRef

  3. 3
    Adewale Fawole, Rafat Abonour, Michael Stender, Seerin Shatavi, Susanna Gaikazian, Joseph Anderson, Ishmael Jaiyesimi, Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?, Leukemia & Lymphoma, 2014, 1

    CrossRef

  4. 4
    G. Fouquet, S. Guidez, C. Herbaux, H. Demarquette, X. Leleu, Myélome multiple indolent, La Revue de Médecine Interne, 2014, 35, 4, 243

    CrossRef

  5. 5
    Nishant Tageja, Elisabet E. Manasanch, Neha Korde, Mary Kwok, Sham Mailankody, Manisha Bhutani, Mark Roschewski, Ola Landgren, Smoldering multiple myeloma: present position and potential promises, European Journal of Haematology, 2014, 92, 1
  6. 6
    María-Victoria Mateos, Jesús F San Miguel, Asymptomatic (smoldering) myeloma: treatment strategy, International Journal of Hematologic Oncology, 2013, 2, 6, 445

    CrossRef

  7. 7
    S Girnius, N C Munshi, Challenges in multiple myeloma diagnosis and treatment, Leukemia Supplements, 2013, 2, S3

    CrossRef

  8. 8
    Constantine S. Mitsiades, Selina Chen-Kiang, Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma, Critical Reviews in Oncology/Hematology, 2013, 88, S5

    CrossRef

  9. 9
    María-Victoria Mateos, Miguel-Teodoro Hernández, Pilar Giraldo, Javier de la Rubia, Felipe de Arriba, Lucía López Corral, Laura Rosiñol, Bruno Paiva, Luis Palomera, Joan Bargay, Albert Oriol, Felipe Prosper, Javier López, Eduardo Olavarría, Nuria Quintana, José-Luis García, Joan Bladé, Juan-José Lahuerta, Jesús-F. San Miguel, Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma, New England Journal of Medicine, 2013, 369, 5, 438

    CrossRef

  10. 10
    O. Landgren, Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies, Hematology, 2013, 2013, 1, 478

    CrossRef

  11. 11
    María-Victoria Mateos, Jesús F. San Miguel, New Approaches to Smoldering Myeloma, Current Hematologic Malignancy Reports, 2013, 8, 4, 270

    CrossRef

  12. 12
    A. Dispenzieri, A. K. Stewart, A. Chanan-Khan, S. V. Rajkumar, R. A. Kyle, R. Fonseca, P. Kapoor, P. L. Bergsagel, A. McCurdy, M. A. Gertz, M. Q. Lacy, J. A. Lust, S. J. Russell, S. R. Zeldenrust, C. Reeder, V. Roy, F. Buadi, D. Dingli, S. R. Hayman, N. Leung, Y. Lin, J. Mikhael, S. K. Kumar, Smoldering multiple myeloma requiring treatment: time for a new definition?, Blood, 2013, 122, 26, 4172

    CrossRef

  13. 13
    S. Vincent Rajkumar, Giampaolo Merlini, Jesus F. San Miguel, Haematological cancer: Redefining myeloma, Nature Reviews Clinical Oncology, 2012, 9, 9, 494

    CrossRef

  14. 14
    Miyuki Takasu, Chihiro Tani, Yasuko Sakoda, Miho Ishikawa, Keizo Tanitame, Shuji Date, Yuji Akiyama, Akira Sakai, Hideki Asaoku, Toshio Kajima, Kazuo Awai, Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results, European Radiology, 2012, 22, 5, 1114

    CrossRef

  15. 15
    Angela Rago, Sara Grammatico, Tommaso Za, Anna Levi, Sergio Mecarocci, Agostina Siniscalchi, Luca De Rosa, Stefano Felici, Velia Bongarzoni, Anna Lina Piccioni, Giacinto La Verde, Francesco Pisani, Luca Franceschini, Anna Lisa Paviglianiti, Tommaso Caravita, Maria Teresa Petrucci, Valerio De Stefano, Giuseppe Cimino, Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form, Cancer, 2012, 118, 22
  16. 16
    Ola Landgren, S. Vincent Rajkumar, Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future, Seminars in Hematology, 2011, 48, 1, 66

    CrossRef

  17. You have free access to this content17
    Jennifer M. Bird, Roger G. Owen, Shirley D’Sa, John A. Snowden, Guy Pratt, John Ashcroft, Kwee Yong, Gordon Cook, Sylvia Feyler, Faith Davies, Gareth Morgan, Jamie Cavenagh, Eric Low, Judith Behrens, Guidelines for the diagnosis and management of multiple myeloma 2011, British Journal of Haematology, 2011, 154, 1
  18. 18
    N. Korde, S. Y. Kristinsson, O. Landgren, Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies, Blood, 2011, 117, 21, 5573

    CrossRef

  19. 19
    Jacob Laubach, Paul Richardson, Kenneth Anderson, Multiple Myeloma, Annual Review of Medicine, 2011, 62, 1, 249

    CrossRef

  20. 20
    Miyuki Takasu, Chihiro Tani, Miho Ishikawa, Shuji Date, Jun Horiguchi, Masao Kiguchi, Akihisa Tamura, Akira Sakai, Hideki Asaoku, Nobuhito Nango, Kazuo Awai, Multiple Myeloma: Microstructural Analysis of Lumbar Trabecular Bones in Patients without Visible Bone Lesions—Preliminary Results, Radiology, 2011, 260, 2, 472

    CrossRef

  21. 21
    S. Vincent Rajkumar, Treatment of multiple myeloma, Nature Reviews Clinical Oncology, 2011, 8, 8, 479

    CrossRef

  22. 22
    Therapie–Handbuch Innere Medizin Sonderedition 2011⁄2012, 2011,

    CrossRef

  23. 23
    Mary Ann Yancey, Adam J. Waxman, Ola Landgren, A Case Study Progression to Multiple Myeloma, Clinical Journal of Oncology Nursing, 2010, 14, 4, 419

    CrossRef

  24. 24
    Davide Rossi, Marco Fangazio, Lorenzo De Paoli, Alessia Puma, Paola Riccomagno, Valeria Pinto, Paola Zigrossi, Antonio Ramponi, Guido Monga, Gianluca Gaidano, Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma, Cancer, 2010, 116, 9
  25. 25
    Adam J. Waxman, Michael Kuehl, Arun Balakumaran, Brendan Weiss, Ola Landgren, Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future, Clinical Lymphoma Myeloma and Leukemia, 2010, 10, 4, 248

    CrossRef

  26. You have free access to this content26
    Francesca Patriarca, Maria T. Petrucci, Sara. Bringhen, Luca Baldini, Tommaso Caravita, Paolo Corradini, Alessandro Corso, Francesco Di Raimondo, Antonietta Falcone, Felicetto Ferrara, Fortunato Morabito, Pellegrino Musto, Massimo Offidani, Mario Petrini, Rita Rizzi, Gianpietro Semenzato, Patrizia Tosi, Angelo Vacca, Michele Cavo, Mario Boccadoro, Antonio Palumbo, Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts, European Journal of Haematology, 2009, 82, 2
  27. 27
    John A. Lust, Martha Q. Lacy, Steven R. Zeldenrust, Angela Dispenzieri, Morie A. Gertz, Thomas E. Witzig, Shaji Kumar, Suzanne R. Hayman, Stephen J. Russell, Francis K. Buadi, Susan M. Geyer, Megan E. Campbell, Robert A. Kyle, S. Vincent Rajkumar, Philip R. Greipp, Michael P. Kline, Yuning Xiong, Laurie L. Moon-Tasson, Kathleen A. Donovan, Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component, Mayo Clinic Proceedings, 2009, 84, 2, 114

    CrossRef

  28. 28
    A Palumbo, O Sezer, R Kyle, J S Miguel, R Z Orlowski, P Moreau, R Niesvizky, G Morgan, R Comenzo, P Sonneveld, S Kumar, R Hajek, S Giralt, S Bringhen, K C Anderson, P G Richardson, M Cavo, F Davies, J Bladé, H Einsele, M A Dimopoulos, A Spencer, A Dispenzieri, T Reiman, K Shimizu, J H Lee, M Attal, M Boccadoro, M Mateos, W Chen, H Ludwig, D Joshua, J Chim, V Hungria, I Turesson, B G M Durie, S Lonial, International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation, Leukemia, 2009, 23, 10, 1716

    CrossRef

  29. 29
    Shaji K. Kumar, Joseph R. Mikhael, Francis K. Buadi, David Dingli, Angela Dispenzieri, Rafael Fonseca, Morie A. Gertz, Philip R. Greipp, Suzanne R. Hayman, Robert A. Kyle, Martha Q. Lacy, John A. Lust, Craig B. Reeder, Vivek Roy, Stephen J. Russell, Kristen E. Detweiler Short, A. Keith Stewart, Thomas E. Witzig, Steven R. Zeldenrust, Robert J. Dalton, S. Vincent Rajkumar, P. Leif Bergsagel, Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines, Mayo Clinic Proceedings, 2009, 84, 12, 1095

    CrossRef

  30. 30
    Sigurdur Yngvi Kristinsson, Ola Landgren, Vincent S. Rajkumar, Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates, The Cancer Journal, 2009, 15, 6, 473

    CrossRef

  31. 31
    Pellegrino Musto, Maria Teresa Petrucci, Sara Bringhen, Tommasina Guglielmelli, Tommaso Caravita, Velia Bongarzoni, Alessandro Andriani, Giovanni D'Arena, Enrico Balleari, Giuseppe Pietrantuono, Mario Boccadoro, Antonio Palumbo, A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma, Cancer, 2008, 113, 7
  32. 32
    K C Anderson, R A Kyle, S V Rajkumar, A K Stewart, D Weber, P Richardson, Clinically relevant end points and new drug approvals for myeloma, Leukemia, 2008, 22, 2, 231

    CrossRef

  33. 33
    Craig P CARDEN, Mark A ROSENTHAL, Immediate versus delayed chemotherapy in patients with asymptomatic incurable metastatic cancer, Asia-Pacific Journal of Clinical Oncology, 2007, 3, 4
  34. 34
    S. Vincent Rajkumar, Martha Q. Lacy, Robert A. Kyle, Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, Blood Reviews, 2007, 21, 5, 255

    CrossRef

  35. 35
    Angela Dispenzieri, S. Vincent Rajkumar, Morie A. Gertz, Martha Q. Lacy, Robert A. Kyle, Philip R. Greipp, Thomas E. Witzig, John A. Lust, Stephen J. Russell, Suzanne R. Hayman, Shaji Kumar, Steven R. Zeldenrust, Rafael Fonseca, P. Leif Bergsagel, Craig B. Reeder, A. Keith Stewart, Vivek Roy, Robert J. Dalton, Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement, Mayo Clinic Proceedings, 2007, 82, 3, 323

    CrossRef

  36. 36
    Angela Dispenzieri, S. Vincent Rajkumar, Morie A. Gertz, Martha Q. Lacy, Robert A. Kyle, Philip R. Greipp, Thomas E. Witzig, John A. Lust, Stephen J. Russell, Suzanne R. Hayman, Shaji Kumar, Steven R. Zeldenrust, Rafael Fonseca, P. Leif Bergsagel, Craig B. Reeder, A. Keith Stewart, Vivek Roy, Robert J. Dalton, Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement, Mayo Clinic Proceedings, 2007, 82, 3, 323

    CrossRef

  37. 37
    Hang Quach, H Miles Prince, Linda Mileshkin, Treatment Strategies in Elderly Patients with Multiple Myeloma, Drugs & Aging, 2007, 24, 10, 829

    CrossRef

  38. 38
    Patrizia Zappasodi, Alessandro Corso, Catherine Klersy, Gianmatteo Pica, Silvia Mangiacavalli, Marzia Varettoni, Chiara Rusconi, Cristiana Pascutto, Mario Lazzarino, Changes in multiple myeloma epidemiology in the last thirty years: A single centre experience, European Journal of Cancer, 2006, 42, 3, 396

    CrossRef

  39. 39
    Bhawna Sirohi, Ray Powles, Epidemiology and outcomes research for MGUS, myeloma and amyloidosis, European Journal of Cancer, 2006, 42, 11, 1671

    CrossRef

  40. 40
    Alastair Smith, Finn Wisloff, Diana Samson, Guidelines on the diagnosis and management of multiple myeloma 2005, British Journal of Haematology, 2006, 132, 4
  41. 41
    S. Vincent Rajkumar, Angela Dispenzieri, Robert A. Kyle, Monoclonal Gammopathy of Undetermined Significance, Waldenström Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment, Mayo Clinic Proceedings, 2006, 81, 5, 693

    CrossRef

  42. 42
    Thierry Facon, Ibrahim Yakoub-Agha, Xavier Leleu, Myélome multiple, EMC - Hématologie, 2006, 1, 1, 1

    CrossRef

  43. 43
    Joan Bladé, Laura Rosiñol, Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance, Current Treatment Options in Oncology, 2006, 7, 3, 237

    CrossRef

  44. 44
    S. Vincent Rajkumar, Robert A. Kyle, Conventional therapy and approach to management, Best Practice & Research Clinical Haematology, 2005, 18, 4, 585

    CrossRef

  45. 45
    Robert A. Kyle, S. Vincent Rajkumar, Monoclonal gammopathies of undetermined significance, Best Practice & Research Clinical Haematology, 2005, 18, 4, 689

    CrossRef

  46. 46
    Angela Dispenzieri, Robert A. Kyle, Multiple myeloma: clinical features and indications for therapy, Best Practice & Research Clinical Haematology, 2005, 18, 4, 553

    CrossRef

  47. 47
    S. Vincent Rajkumar, Robert A. Kyle, Multiple Myeloma: Diagnosis and Treatment, Mayo Clinic Proceedings, 2005, 80, 10, 1371

    CrossRef

  48. 48
    Erik Hippe, Jan Westin, Finn Wislöff, Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care, European Journal of Haematology, 2005, 74, 3
  49. 49
    Wee J. Chng, Rafael Fonseca, Risk Stratification of Patients with Newly Diagnosed Multiple Myeloma: Optimizing Treatment Based on Pretreatment Characteristics, Clinical Lymphoma and Myeloma, 2005, 6, 3, 200

    CrossRef

  50. 50
    Robert A. Kyle, S. Vincent Rajkumar, Multiple Myeloma, New England Journal of Medicine, 2004, 351, 18, 1860

    CrossRef

  51. 51
    Multiple Myeloma and Related Disorders, 2004,

    CrossRef

  52. 52
    Ambuj Kumar, Thomas Loughran, Melissa Alsina, Brian GM Durie, Benjamin Djulbegovic, Management of multiple myeloma: a systematic review and critical appraisal of published studies, The Lancet Oncology, 2003, 4, 5, 293

    CrossRef

  53. 53
    Robert A. Kyle, S. Vincent Rajkumar, Monoclonal gammopathies of undetermined significance: a review, Immunological Reviews, 2003, 194, 1
  54. 54
    L. Rosiñol, J. Bladé, J. Esteve, M. Aymerich, M. Rozman, S. Montoto, E. Giné, E. Nadal, X. Filella, R. Queralt, A. Carrió, E. Montserrat, Smoldering multiple myeloma: natural history and recognition of an evolving type, British Journal of Haematology, 2003, 123, 4
  55. 55
    S.Vincent Rajkumar, Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease, Seminars in Hematology, 2003, 40, 17

    CrossRef

  56. 56
    S. Vincent Rajkumar, Morie A. Gertz, Robert A. Kyle, Philip R. Greipp, Current Therapy for Multiple Myeloma, Mayo Clinic Proceedings, 2002, 77, 8, 813

    CrossRef

  57. 57
    Jean-Luc Harousseau, MANAGEMENT OF MULTIPLE MYELOMA, Reviews in Clinical and Experimental Hematology, 2002, 6, 3
  58. 58
    Robert A. Kyle, S. Vincent Rajkumar, MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE, Reviews in Clinical and Experimental Hematology, 2002, 6, 3
  59. 59
    Deborah T Blumenthal, Martha J Glenn, Neurologic Manifestations of Hematologic Disorders, Neurologic Clinics, 2002, 20, 1, 265

    CrossRef

  60. 60
    Donna M. Weber, Newly diagnosed multiple myeloma, Current Treatment Options in Oncology, 2002, 3, 3, 235

    CrossRef

  61. 61
    Diagnosis and management of multiple myeloma, British Journal of Haematology, 2001, 115, 3
  62. 62
    Nelida N. Sjak-Shie, Robert A. Vescio, James R. Berenson, Recent advances in multiple myeloma, Current Opinion in Hematology, 2000, 7, 4, 241

    CrossRef

  63. 63
    Philip R. Greipp, Smoldering, asymptomatic stage 1, and indolent myeloma, Current Treatment Options in Oncology, 2000, 1, 2, 119

    CrossRef

  64. 64
    Xavier Mariette, Anne-Marie Zagdanski, Ali Guermazi, Catherine Bergot, Anne Arnould, Jacques Frija, Jean-Claude Brouet, Jean-Paul Fermand, Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma, British Journal of Haematology, 1999, 104, 4
  65. 65
    Frédéric E. Lecouvet, Jacques Malghem, Lucienne Michaux, Baudouin Maldague, Augustin Ferrant, Jean-Louis Michaux, Bruno C. Vande Berg, Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey, British Journal of Haematology, 1999, 106, 1
  66. 66
    Mario Boccadoro, Alessandro Pileri, 1Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis, Baillière's Clinical Haematology, 1995, 8, 4, 705

    CrossRef

  67. 67
    Daniel E. Bergsagel, 5The role of chemotherapy in the treatment of multiple myeloma, Baillière's Clinical Haematology, 1995, 8, 4, 783

    CrossRef

  68. 68
    D. Peest, H. Deicher, R. Coldewey, R. Leo, R. Bartl, H. Bartels, H.J. Braun, W. Fett, J.T. Fischer, B. Göbel, P. Harms, R. Henke, L. Hoffmann, E.D. Kreuser, W.D. Maier, C.R. Meier, J. Oertel, M. Petit, M. Planker, C. Platzeck, M. Respondek, E. Schäfer, K. Schumacher, M. Stennes, W. Stenzinger, C. Tirier, H. Wagner, H.J. Weh, P. von Wussow, J. Wysk, A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group, European Journal of Cancer, 1995, 31, 2, 146

    CrossRef

  69. 69
    C. Galen Choy, Ruben Niesvizky, Joseph Michaeli, Multiple Myeloma, Clinical Immunotherapeutics, 1995, 4, 5, 346

    CrossRef

  70. 70
    T. Facon, J.F. Menard, J.L. Michaux, L. Euller-Ziegler, J.F. Bernard, B. Grosbois, A. Daragon, I. Azais, Y. Courouble, G. Kaplan, J.P. Laporte, A. De Gramont, B. Duclos, A. Leonard, P. Mineur, A. Delannoy, J.P. Jouet, F. Bauters, M. Monconduit, Prognostic factors in low tumour mass asymptomatic multiple myeloma: A report on 91 patients, American Journal of Hematology, 1995, 48, 2
  71. 71
    Alastair J.J. Wood, Raymond Alexanian, Meletios Dimopoulos, The Treatment of Multiple Myeloma, New England Journal of Medicine, 1994, 330, 7, 484

    CrossRef

  72. 72
    Yulong He, Keith Wheatley, Axel Glasmacher, Hamish Ross, Benjamin Djulbegovic, Early versus deferred treatment for early stage multiple myeloma, The Cochrane Library,